10x Genomics, Inc. - TXG STOCK NEWS

10x Genomics, Inc. (Nasdaq: TXG) has appointed Jim Wilbur, Ph.D., as the new Chief Commercial Officer, effective July 27, 2022. With nearly 30 years of experience in building businesses and leading commercial teams, Wilbur will enhance the company’s commercial strategy and execution. Previously at Meso Scale Discovery, he led the commercial functions and achieved significant growth. Wilbur is optimistic about 10x's potential in single cell and spatial biology and aims to drive a culture of commercial excellence.

10x Genomics, Inc. (Nasdaq: TXG) announced preliminary revenue of approximately $114.5 million for Q2 2022, marking a 1% decrease year-over-year. Geographic revenue breakdown shows Americas at $70.9 million (+8%), EMEA at $25.6 million (-11%), and APAC at $18.1 million (-15%). CEO Serge Saxonov noted that results fell short of expectations but expressed confidence in future growth. The company will provide a full financial outlook on August 8, 2022, during their earnings call.

10x Genomics (TXG) announced significant product advancements at the AGBT General Meeting, showcasing its leadership in single-cell and spatial analysis. The company introduced the Fixed RNA Profiling Kit, enabling single-cell RNA sequencing from FFPE tissues for the first time, and announced preorders for the Visium CytAssist, its first spatial instrument. Furthermore, the Xenium In Situ Analyzer is set to ship by year-end, enhancing in situ analysis capabilities. These innovations underscore TXG's commitment to advancing research in genomics and biology.

Fanatics has appointed Lydia Jett and Jonathan Mildenhall to its board of directors, bringing extensive experience from fintech, e-commerce, and marketing sectors. Jett, from SoftBank, played a crucial role in Fanatics' growth since their initial $1 billion investment in 2017. Mildenhall, former CMO of Airbnb, is noted for transforming brand strategies. Both directors will guide Fanatics in expanding its diverse portfolio, which includes licensed merchandise, digital collectibles, and online sports betting. Additionally, Fanatics released its first ESG report, highlighting its commitment to sustainability and social responsibility.

10x Genomics, Inc. (Nasdaq: TXG) reported Q1 2022 revenue of $114.5 million, an 8% increase year-over-year. The growth stemmed from higher consumables and instrument sales, particularly the Chromium X Series. However, gross margin decreased to 78% from 84%, attributed to product mix changes and rising costs. Operating expenses rose 32% to $130.8 million, leading to an operating loss of $41.7 million and a net loss of $42.4 million. The company maintains its revenue guidance of $600 million to $630 million for 2022, projecting 22% to 28% growth.

On April 26, 2022, 10x Genomics (Nasdaq: TXG) announced their participation in the BofA Securities 2022 Healthcare Conference in Las Vegas. The management team will engage in a fireside chat on May 10 at 8:40 a.m. PT. A live and archived webcast of this presentation will be accessible through the company's website. 10x Genomics specializes in innovative life science technology aimed at understanding biological systems, with their products widely used by leading research institutions and pharmaceutical companies globally.

10x Genomics (TXG) announced the launch of the Fixed RNA Profiling Kit and Nuclei Isolation Kit on April 14, 2022. These products enhance sample preparation workflows for single cell analysis, targeting the challenges in handling fragile human tissues and frozen samples. The Fixed RNA Profiling Kit allows researchers to store samples post-collection without cryopreservation, while the Nuclei Isolation Kit simplifies the extraction of nuclei from frozen tissue, making the process more efficient. Both kits are set to ship mid-May 2022, aiming to broaden the use of single cell analysis in research.

10x Genomics (Nasdaq: TXG) will report its financial results for Q1 2022 after market close on May 4, 2022. A conference call to discuss these results, along with business developments and future outlook, will begin at 1:30 p.m. PT / 4:30 p.m. ET. The live audio of the webcast will be accessible through the company's website and archived for 45 days. 10x Genomics focuses on life science technology advancements, with significant adoption in top global research institutions and pharmaceutical companies.

10x Genomics (Nasdaq: TXG) will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. The company's management will engage in a virtual fireside chat to discuss business activities. Interested parties can access the live and archived webcast through the company's website.

Recognized for advancing human health, 10x Genomics provides integrated solutions for biological analysis, widely used by premier research institutions and pharmaceutical companies globally.